The controversy of neoadjuvant therapy in rectal cancer
Cir Esp (Engl Ed). 2019 Aug-Sep;97(7):361-363.
doi: 10.1016/j.ciresp.2019.01.004.
Epub 2019 Feb 14.
[Article in
English,
Spanish]
Affiliations
- 1 Medical Oncology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, España. Electronic address: jmaurel@clinic.cat.
- 2 Medical Oncology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, España.
- 3 Gastrointestinal and Pancreatic Oncology Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España.
No abstract available
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Chemoradiotherapy
-
Chemotherapy, Adjuvant / methods
-
Humans
-
Magnetic Resonance Imaging
-
Neoadjuvant Therapy*
-
Neoplasm Recurrence, Local*
-
Organoplatinum Compounds / therapeutic use
-
Pyridines / therapeutic use
-
Pyrimidines / therapeutic use
-
Rectal Neoplasms / diagnostic imaging
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / therapy
-
Tumor Microenvironment / immunology
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Pyridines
-
Pyrimidines
-
oxiplatin